Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention JACC Review Topic of the Week
Sullivan AE, Nanna MG, Wang TY, Bhatt DL, Angiolillo DJ, Mehran R, Banerjee S, Cantrell S, Jones WS, Rymer JA, Washam JB, Rao SV, Ohman EM. Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention JACC Review Topic of the Week. Journal Of The American College Of Cardiology 2021, 78: 1550-1563. PMID: 34620413, DOI: 10.1016/j.jacc.2021.08.013.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateEptifibatideHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRisk FactorsStentsThromboembolismTirofibanConceptsDual antiplatelet therapyAntiplatelet therapyBridging therapySmall-molecule glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIntravenous antiplatelet agentsOptimal antiplatelet strategyPerioperative risk factorsCoronary stent implantationMultidisciplinary risk assessmentIntravenous P2YEarly surgeryHemorrhagic complicationsAntiplatelet strategiesClinical characteristicsAntiplatelet agentsPerioperative careRisk stratificationComplex patientsStent implantationRisk factorsCurrent guidelinesOptimal managementTherapy